According to information released on Altria's official website, on the evening of March 6th, Altria Group Inc announced that it will acquire the third largest e-cigarette company in the United States, NJOY, for approximately $2.75 billion in cash.
Altria introduced NJOY and mentioned their partnership with Reynolds, stating that NJOY will continue to collaborate with Reynolds in the electronic vaping industry under Altria's ownership.
It is reported that this is the second investment in a leading electronic cigarette brand following its investment in Juul. Previously, it exchanged 35% of its shares in Juul for some of its company's heated tobacco intellectual property rights, officially ending its investment in Juul. According to 2FIRSTS, NJOY has a total of 6 products that have received PMTA approval from the FDA.
On February 27th, The Wall Street Journal reported that Altria Group was in talks to acquire NJOY, the third largest e-cigarette brand in the US, for $2.75 billion, citing anonymous sources. However, details of the negotiations were not made public at the time.
2FIRSTS will follow up with further coverage. Stay tuned.
Related news:
Altria announces formal exit from JUUL by exchanging 35% equity for intellectual property rights.
Altria plans to acquire NJOY, the third-largest electronic cigarette company in the United States, for $2.75 billion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
